The **Novavax Covid vaccine**, first approved in August 2022, utilizes older vaccine technology and has shown **fewer side effects** than mRNA vaccines.
Many individuals report experiencing **flu-like symptoms** after receiving mRNA boosters, which affects their willingness to get vaccinated.
Despite its effectiveness - nearly **90% at preventing Covid** - Novavax has seen low uptake with only **83,000 doses** administered versus millions of mRNA doses.
Experts stress that Novavax is **not a second-line option**, highlighting its equivalence to mRNA vaccines and potential advantages regarding side effects.
Current statistics reveal that **over half of Americans** are hesitant to receive a Covid booster, mainly due to concerns over side effects.
For more information, visit the original article here.